<DOC>
	<DOCNO>NCT00107913</DOCNO>
	<brief_summary>This study design evaluate efficacy safety single agent Doxil treatment patient refractory ITP ( Idiopathic Thrombocytopenic Purpura ) .</brief_summary>
	<brief_title>Study Doxil Treatment Patients With Refractory Idiopathic Thrombocytopenic Purpura</brief_title>
	<detailed_description>Eligible patient receive Doxil 20 mg/m2 IV 1 hour every 2 week . Treatment continue 1 course beyond return platelet count normal maximum 18 course .</detailed_description>
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Thrombocytopenia bone marrow finding show normal increased number megakaryocyte . Failure respond initial treatment steroid , IV immune globulin , splenectomy post splenectomy steroid . Platelet count 30,000 less . Performance status score 2 less . Adequate organ function : *bilirubin &lt; 2 ; *AST &lt; 3 time normal ; *creatinine &lt; 2 . No prior treatment anthracycline chemically related drug . Pregnant lactate woman . Presence malignancy basal cell carcinoma skin .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2005</verification_date>
	<keyword>Immune Thrombocytopenic Purpura</keyword>
</DOC>